Patents by Inventor Susan M. Freier

Susan M. Freier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150167005
    Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
    Type: Application
    Filed: November 12, 2014
    Publication date: June 18, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
  • Patent number: 9057066
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: June 16, 2015
    Assignees: Isis Pharmaceuticals, Inc., CHDI Foundation Inc.
    Inventors: Gene Hung, Janet M. Leeds, C. Frank Bennett, Susan M. Freier
  • Publication number: 20150159155
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: October 30, 2014
    Publication date: June 11, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Publication number: 20150152411
    Abstract: Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, ameliorate diseases, disorders or conditions related to apo(a) or Lp(a). Certain diseases, disorders or conditions related to apo(a) or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The antisense compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Application
    Filed: May 23, 2013
    Publication date: June 4, 2015
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Susan M. Freier
  • Publication number: 20150141493
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GCCR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.
    Type: Application
    Filed: October 24, 2014
    Publication date: May 21, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Susan M. Freier, Sanjay Bhanot
  • Patent number: 9034842
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of PTP1B mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: May 19, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Susan M. Freier
  • Patent number: 9034841
    Abstract: Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: May 19, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Susan M. Freier, Michael L. McCaleb
  • Patent number: 9029337
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 7 and treating or preventing thromboembolic complications, hyperproliferative disorders, or inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 7 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, cancer, rheumatoid arthritis, and fibrosis.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: May 12, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Chenguang Zhao
  • Publication number: 20150105444
    Abstract: The present invention provides compounds comprising oligonucleotides complementary to a fibronectin transcript. Certain such compounds are useful for hybridizing to a fibronectin transcript, including but not limited to a fibronectin transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the fibronectin transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with fibrosis. In certain embodiments, such compounds are used to treat one or more symptoms associated with renal fibrosis.
    Type: Application
    Filed: June 3, 2013
    Publication date: April 16, 2015
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Frank Rigo
  • Patent number: 9006198
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: April 14, 2015
    Assignees: Isis Pharmaceuticals, Inc., The University of British Columbia
    Inventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
  • Publication number: 20150099792
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GCGR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.
    Type: Application
    Filed: September 12, 2014
    Publication date: April 9, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Susan M. Freier, Sanjay Bhanot
  • Publication number: 20150094461
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Application
    Filed: December 15, 2014
    Publication date: April 2, 2015
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey
  • Publication number: 20150087691
    Abstract: Disclosed herein are methods for decreasing AIAT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of fibrosis. Disclosed herein are methods for decreasing AIAT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of liver disease, such as, AIATD associated liver disease, and pulmonary disease, such as, AIATD associated pulmonary disease in an individual in need thereof. Methods for inhibiting AIAT mRNA and protein expression can also be used as a prophylactic treatment to prevent individuals at risk for developing a liver disease, such as, AIATD associated liver disease and pulmonary disease, such as, AIATD associated pulmonary disease.
    Type: Application
    Filed: March 19, 2013
    Publication date: March 26, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Brett P. Monia, Michael L. McCaleb, Susan M. Freier, Shuling Guo
  • Patent number: 8957040
    Abstract: Disclosed herein are antisense compounds and methods for selectively of reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative, such as Huntington's Disease (HD).
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: February 17, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Sarah Greenlee, Eric E. Swayze
  • Patent number: 8952145
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's Disease (HD) progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntington's Disease (HD) in an individual susceptible to Huntington's Disease (HD). Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: February 10, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • Patent number: 8946179
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: February 3, 2015
    Assignee: Regulus Therapeutics, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey
  • Publication number: 20150031747
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor VII and treating, preventing, or slowing progression of thromboembolic complications, hyperproliferative disorders, or inflammatory conditions in an individual in need thereof.
    Type: Application
    Filed: February 8, 2013
    Publication date: January 29, 2015
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Susan M. Freier
  • Patent number: 8921331
    Abstract: Methods for slowing disease progression in an individual suffering from familial ALS are provided. Also provided are methods of increasing the survival time of an individual suffering from familial ALS. These methods employ antisense oligonucleotides targeted to SOD1, for use in inhibiting the expression of SOD1 in the central nervous system of an individual suffering from familial ALS.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: December 30, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Kenneth W. Dobie
  • Publication number: 20140378533
    Abstract: Disclosed herein are antisense compounds, compositions and methods for modulating an RNA target by targeting a repetitive sequence in the RNA target and modulating an associated disease, disorder and/or condition related to such RNA target. Also disclosed herein are methods of identifying such compounds and compositions.
    Type: Application
    Filed: February 8, 2013
    Publication date: December 25, 2014
    Applicant: Isis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • Patent number: 8916531
    Abstract: Disclosed herein are antisense compounds and methods for decreasing CD40. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to CD40 include hyperproliferative disorders, graft versus host disease (GVHD), graft rejection, asthma, airway hyperresponsiveness, chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), and certain forms of arthritis.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: December 23, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert, Susan M. Freier